In this article, we will take a detailed look at 10 stocks with at least $20 million in insider spending recently. We previously covered 10 stocks with at least $10 million in insider spending recently.
As the stock market navigates a complex environment shaped by recent trade policies, mixed economic signals, and new geopolitical circumstances, investors must remain vigilant. While many experts raise concerns about potential increased volatility under Trump, some analysts believe he is the most pro-stock market president in U.S. history.
On Monday, one day before Trump’s 25% tariffs on goods imported from Canada and Mexico into the U.S. were set to take effect, markets declined. The broader market fell 1.8%, marking its biggest one-day drop of the year, while tech stocks saw a 2.6% decline.
“No room left for Mexico or for Canada,” Trump said at the White House on Monday. “The tariffs, you know, they’re all set. They go into effect tomorrow.”
With no certainty about how long these fluctuations will continue, investors seem to be growing more cautious. While it’s difficult to predict what will happen next, some experts believe that the U.S. Federal Reserve might cut interest rates.
Equity strategists in a Reuters poll project that the broader market will finish the year 9% higher than its current level. Morgan Stanley’s Andrew Slimmon suggests that the adoption of AI could lead to a productivity boom, similar to what happened with the Internet in the late 1990s.
Amid market fluctuations and uncertainty, insider trading also comes into focus. Executives and insiders, with their valuable insights into company strategy, plans, and future moves, may have trades worth analyzing. For example, when a CEO or CFO invests their own money in company shares, it can signal strong confidence in the company’s potential.
However, it is important to highlight that both insider buying and selling can be driven by various motives; therefore, these actions should be considered only within a broader context of the company’s fundamentals, industry trends, and market conditions. This is why due diligence is crucial before making any investment. Insider trading activity, along with other relevant factors, can offer valuable insights into a company’s capabilities, helping investors make more informed decisions.
A close-up of a computer monitor showcasing the trading of digital currency.
Today, we will focus on stocks that have seen at least $20 million in insider spending recently. For this purpose, we used Insider Monkey’s insider trading stock screener, focusing on stocks where at least one insider purchase over the last three months was valued at $20 million or more. Although the total value of insider purchases during this period may be higher, only those worth $20 million or more were considered in this search. Since there were more than 10 stocks meeting this criterion, we selected the 10 stocks with insider purchases ranging from $20 million to $35 million, choosing those with the highest amounts within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual purchase, the number of insider purchases between $20 million and $35 million over the last three months and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $20 million in insider spending recently.
10. Assembly Biosciences, Inc. (NASDAQ:ASMB)
Highest Individual Purchase: $20,098,463.63
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $77.74 million
We begin this list of 10 stocks with significant insider investments recently with a biotechnology company that focuses on developing treatments for viral diseases. Among Assembly Biosciences’ leading candidates is ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor, which is in Phase 1a/1b clinical trial to treat recurrent genital herpes, and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
In February, the company announced positive interim Phase 1a results in healthy participants from its ongoing Phase 1a/b study of ABI-1179, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes.
“In Phase 1a, ABI-1179 and ABI-5366 both exceeded our target pharmacokinetic profile for our long-acting helicase-primase inhibitor program, and we are pleased to advance these two promising candidates with the potential to improve treatment outcomes for individuals with recurrent genital herpes,” stated Jason Okazaki, chief executive officer and president of Assembly Biosciences. “We look forward to reporting Phase 1b interim data for both candidates this fall, which will inform critical next steps in our data-driven portfolio strategy for this important indication.”
On December 19, one investor acquired $20.1 million worth of Assembly Biosciences’ shares, at a price of $21.37 per share. The stock is currently trading at $12.23, having declined 22.50% since the beginning of the year.
Two analysts have an average “Buy” rating on Assembly Biosciences stock, according to StockAnalysis. Experts have also set a 12-month price target of $35, reflecting an increase of 186.18% from the previous price.
For the third quarter of 2024, the company reported revenue from collaborative research of $6.8 million, compared to no revenue recognized in the same period of 2023. Net loss attributable to common stockholders was $9.6 million, or $1.51 per basic and diluted share, compared to $14.4 million, or $3.29 per basic and diluted share in the same quarter of the prior year. At the end of the reporting period, cash, cash equivalents and marketable securities were $95.0 million, compared to $109.2 million as of June 30, 2024.
9. Solid Biosciences Inc. (NASDAQ:SLDB)
Highest Individual Purchase: $20,150,000.00
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $426.21 million
Solid Biosciences is a life science company, engaged in the development of therapies for neuromuscular and cardiac diseases in the U.S. The Charleston, Massachusetts-based company has several leading product candidates in the pipeline. One of them is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; another one is SGT-501, designed to help with Catecholaminergic polymorphic ventricular tachycardia.
The stock was also among 14 stocks with heavy insider buying in 2024.
On February 19, one insider purchased $20.15 million worth of Solid Biosciences shares at $4.03 per share. This acquisition was part of the company’s underwritten offering of 35.74 million shares of its common stock. The company said it expected $200 million in the aggregate gross proceeds of the offering. Currently, the stock is trading at $5.12, having gained 28% year-to-date.
In February, Solid Biosciences also announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003. Interim 90-day biopsy data reported in the first three participants showed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple biomarkers that are indicators of muscle health and resilience.
“Three different measurement methodologies showed what we believe to be potential best-in-class expression of our differentiated microdystrophin transgene,” commented Bo Cumbo, president and CEO of Solid Biosciences. Cumbo also added in mid-2025 the company plans to talk with the FDA about the potential for an accelerated approval regulatory pathway for SGT-003.
Nine Wall Street analysts have given an average “Strong Buy” for Solid Biosciences, writes TipRanks. Their average price target is $16.86, indicating a 229.3% increase from the previous price.
8. PIMCO Dynamic Income Strategy Fund (NYSE:PDX)
Highest Individual Purchase: $20,195,499.60
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $1.13 billion
Eighth among 10 stocks with at least $20 million in insider spending recently is a closed-end fund, PIMCO Dynamic Income Strategy Fund.
There may be several reasons why PIMCO has limited analyst coverage, for example, it could be because it is a closed-end type of fund, and not an open-end mutual fund or ETF which are known to have more attention from analysts. Sometimes, the fund’s established reputation is enough for its funds to attract investors, and expert coverage may be unnecessary.
On January 13, one investor bought $20.2 million worth of PIMCO shares for $27.60 per share. The fund is currently trading at $24.80 per share, having dropped 5.09% since the beginning of the year. Over the last 12 months, PIMCO returned 21.75% to its investors.
7. Sionna Therapeutics, Inc. (NASDAQ:SION)
Highest Individual Purchase: $20,250,000.00
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $611 million
Sionna Therapeutics is a cystic fibrosis (CF) focused biopharmaceutical company. The Boston, Massachusetts-based company is working on new treatments that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Its goal is to create various medicines for people with CF that will restore CFTR function to nearly normal.
The company’s co-founders bring over a decade of research experience in this field, and Sionna is focused on developing a pipeline of small molecules designed to address the defects caused by the most prevalent CF genetic mutation.
Since this is a new stock on the market, analyst coverage is very limited, and there are no public finance reports available yet.
Sionna is also among 10 stocks insiders are buying this year.
6. Atai Life Sciences N.V. (NASDAQ:ATAI)
Highest Individual Purchase: $22,755,007.80
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $290.99 million
Atai Life Sciences N.V. is a psychedelics company. It is focused on developing and investing in various treatments for depression, anxiety, addiction, and other mental health disorders. Among its leading product candidates are COMP360, a proprietary psilocybin, which is in the Phase 3 program, and VLS-01, a DMT treatment for treatment-resistant depression.
The company, headquartered in New York and Berlin is also considered one of 12 best psychedelic stocks to buy in 2025.
On February 14, one insider acquired $22.76 million worth of Atai shares at a price of $2.10 per share. Currently, the stock is trading at $1.50 per share, having gained 12.78% year-to-date.
For the third quarter of 2024, Atai reported cash, cash equivalents, restricted cash and short-term securities of $101.0 million compared to $154.2 million as of December 31, 2023. The company attributed the decrease to $58.1 million net cash used in operating activities, $10.0 million for the Beckley Psytech investment, and a $7.7 million investment to advance its programs, among others. Atai stated that its cash position is enough to support operations into 2026. Net loss amounted to $26.3 million, compared to a net income of $44.2 million in the same quarter of 2023.
Four analysts have an average “Strong Buy” on Atai stock, with a 12-month stock target of $9. This reflects a 500% increase from the previous price, according to StockAnalysis.
5. Metsera, Inc. (NASDAQ:MTSR)
Highest Individual Purchase: $25,780,032.00
Number of Purchases Worth Between $20 million and $35 million: 2
Market Capitalization: $2.94 billion
In the middle of the list of 10 stocks with at least $20 million in insider spending recently is a New York City-based clinical-stage biotechnology company, Metsera. The company is focused on developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. It has a broad portfolio of therapies with the potential to address various therapeutic targets and meet the requirements of the weight loss treatment industry. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.
The company went public in February, raising $257 million, pricing shares above its targeted range. During the IPO, two investors acquired $25.78 million worth of Metsera shares each, at a price of $18 per share. Currently, the stock is trading at $28.50 per share, having gained 7.55% since the IPO.
In January, the company shared encouraging results from a 12-week Phase 2a clinical trial of its primary candidate, MET-097i, a potential once-monthly injectable treatment for obesity. The data showed that MET-097i helped participants lose weight, with some shedding up to 20% of their body weight, and it was well tolerated with only mild side effects. The company intends to conduct additional studies in 2025.
Considering this is a stock that recently went public, analyst coverage is, so far, limited.
Metsera is also one of the 10 stocks insiders spent the most money on recently.
4. TKO Group Holdings, Inc. (NYSE:TKO)
Highest Individual Purchase: $26,001,524.32
Number of Purchases Worth Between $20 million and $35 million: 6
Market Capitalization: $12.29 billion
The sports and entertainment giant, TKO Group, was created by Endeavor (NYSE:EDR) as part of a merger between World Wrestling Entertainment and Zuffa, LLC, the parent company of the Ultimate Fighting Championship. The New York and Beverly Hills, California-based company produces and licenses live events, TV programs, long- and short-form content, reality series, and more. Its diverse content reaches more than 1 billion households across around 210 countries and territories. Each year, the company organizes more than 300 live events, attracting more than two million fans.
In February, the company announced that UFC and Monster Energy have signed a multiyear renewal of their long-standing partnership, under which Monster will continue as the exclusive global Offical Energy Drink of UFC.
In December, three insiders, including the CEO, made several investments in the company. Three investments amounted to $26 million each, acquiring 176,833 shares for $147.04 per share. Currently, the stock is trading at $147.79, having gained 4% since the beginning of the year.
For full year 2024, TKO Group disclosed revenue of $2.804 billion, net income of $6.4 million and adjusted EBITDA of $1.251 billion.
According to 15 analysts, the average rating for TKO Group stock is “Strong Buy.” A 12-month price target is $152.38, writes StockAnalysis. The financial data for 2023 is unavailable, because the company went public in September 2023.
TKO Group is also one of 11 most expensive stocks insiders are buying recently.
3. Custom Truck One Source, Inc. (NYSE:CTOS)
Highest Individual Purchase: $32,574,540.00
Number of Purchases Worth Between $20 million and $35 million: 2
Market Capitalization: $932.7 million
The third stock with significant recent insider investment is a single-source provider of specialized truck and heavy equipment solutions, such as sales, rentals, and financing. Custom Truck One Source operates through three segments: Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS).
In December, two insiders each purchased $32.57 million worth of Custom Truck One Source shares at a price of $4 per share. At the moment, the stock is trading at $4.14, having lost 13.93% year-to-date.
For the third quarter of 2024, Custom Truck disclosed revenue of $447.2 million, up by 5.7% from the previous quarter. Net loss amounted to $17.4 million, a decrease of 28.9% compared to the second quarter of the year. Gross profit was $91.8 million, representing an increase of $2.6 million from the previous quarter.
The company’s leadership anticipates that the growing demand for electricity driven by AI and data centers will create a long-term growth opportunity. Industry reports project a 24% to 29% increase in electricity demand in the United States by 2035.
Four analysts have an average “Moderate Buy” rating on Custom Truck stock, with a 12-month price target of $5.63, according to MarketBeat.
Custom Truck is also one of the 12 best long-term penny stocks to buy according to hedge funds.
2. Tectonic Therapeutic, Inc. (NASDAQ:TECX)
Highest Individual Purchase: $33,000,000.00
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $466.22 million
Second among 10 stocks with at least $20 million in insider spending over the last three months is Tectonic Therapeutic. This is a biotechnology company engaged in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs).
Leveraging its proprietary technology platform, GEODe, the Watertown, Massachusetts-based company is developing innovative biological therapeutics aimed at harnessing the human body to alter the progression of disease. Tectonic primarily focuses on medical conditions with few or no available treatment options. The company was co-founded by Timothy A. Springer and Andrew C. Kruse from Harvard Medical School.
In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin fusion protein designed to help improve heart and lung function. The results showed that a single intravenous dose of TX45 led to significant improvements in heart and lung function in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The treatment was well tolerated, with no serious or severe side effects reported.
On February 5, one insider acquired $33 million worth of Tectonic shares at a price of $50 per share. The purchase was part of the company’s $185 million private placement. The stock has lost 49.30% year-to-date and is now trading at $23.41 per share.
Five analysts have an average “Strong Buy” rating on Tectonic stock, according to data from StockAnalysis. The average 12-month price target is $80.5 per share, representing a 243.87% increase from the latest price.
1. Revolution Medicines, Inc. (NASDAQ:RVMD)
Highest Individual Purchase: $34,999,974.00
Number of Purchases Worth Between $20 million and $35 million: 2
Market Capitalization: $7.57 billion
First among 10 stocks with at least $20 million in insider spending recently is a clinical-stage oncology company that focuses on providing targeted therapies for RAS-driven cancers, Revolution Medicines. Redwood City, California-based company’s pipeline includes RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. Its several RAS(ON) inhibitors are, currently, in clinical development.
On December 5, one insider acquired $35 million worth of Revolution Medicines shares at a price of $46 per share. The purchase was part of the company’s $750 million stock offering. The company planned to sell more than 14.1 million shares at $46 each, plus pre-funded warrants for an additional 2.17 million shares. Prominent banks like JP Morgan and Goldman Sachs led the deal.
Currently, the stock is trading at $38.34 per share, having declined 12.35% since the beginning of the year.
For 2024, the company disclosed zero revenue, compared to $11.6 million in 2023. The decrease in revenue was due to the termination of the company’s collaboration agreement with Sanofi in 2023. Net loss was $600.1 million, compared to net loss of $436.4 million in 2023.
Thirteen analysts have an average “Buy” rating on Revolution stock, with a price target of $66.31, according to MarketBeat.
Overall, RVMD is first among the 10 stocks with at least $20 million in insider spending recently. While we acknowledge the potential of RVMD, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
